Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Nkarta Inc (NKTX)

Nkarta Inc (NKTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 435,072
  • Shares Outstanding, K 33,010
  • Annual Sales, $ 0 K
  • Annual Income, $ -86,080 K
  • 60-Month Beta 0.01
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.78
Trade NKTX with:

Options Overview Details

View History
  • Implied Volatility 123.23% ( +8.79%)
  • Historical Volatility 69.54%
  • IV Percentile 61%
  • IV Rank 35.14%
  • IV High 202.74% on 01/20/22
  • IV Low 80.16% on 03/17/22
  • Put/Call Vol Ratio 1.10
  • Today's Volume 185
  • Volume Avg (30-Day) 477
  • Put/Call OI Ratio 0.49
  • Today's Open Interest 11,465
  • Open Int (30-Day) 15,759

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/22
See More
  • Average Estimate -0.60
  • Number of Estimates 6
  • High Estimate -0.56
  • Low Estimate -0.66
  • Prior Year -0.66
  • Growth Rate Est. (year over year) +9.09%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.10 +18.74%
on 06/16/22
15.73 -16.18%
on 06/08/22
-0.43 (-3.16%)
since 06/01/22
3-Month
7.55 +74.57%
on 04/22/22
20.35 -35.23%
on 04/28/22
+1.74 (+15.21%)
since 04/01/22
52-Week
7.55 +74.57%
on 04/22/22
40.64 -67.57%
on 08/09/21
-17.49 (-57.03%)
since 07/01/21

Most Recent Stories

More News
Wall Street Analysts Predict a 209% Upside in Nkarta, Inc. (NKTX): Here's What You Should Know

The consensus price target hints at a 209.4% upside potential for Nkarta, Inc. (NKTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate...

NKTX : 13.18 (+6.98%)
Nkarta to Participate at Upcoming Investor Conference

SOUTH SAN FRANCISCO, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural...

NKTX : 13.18 (+6.98%)
What Makes Nkarta, Inc. (NKTX) a New Buy Stock

Nkarta, Inc. (NKTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

NKTX : 13.18 (+6.98%)
Can Nkarta, Inc. (NKTX) Climb 383% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 383.4% in Nkarta, Inc. (NKTX). While the effectiveness of this highly sought-after metric is questionable, the positive...

NKTX : 13.18 (+6.98%)
Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development

SOUTH SAN FRANCISCO, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing...

NKTX : 13.18 (+6.98%)
Nkarta Reports First Quarter 2022 Financial Results and Corporate Highlights

Positive preliminary data reported from NKX101 Phase 1 study in patients with relapsed / refractory AML; 3 of 5 patients treated with a 3-dose regimen of...

NKTX : 13.18 (+6.98%)
2 Red-Hot Stocks That Soared More Than 60% in April

Could these be the next big meme stocks?

NKTX : 13.18 (+6.98%)
RDBX : 6.11 (-17.43%)
Novartis Is Looking for Deals. Are These 3 Biotechs on Its List?

CEO Vas Narasimhan is seeking acquisitions under $2 billion.

NVS : 84.36 (-0.20%)
NKTX : 13.18 (+6.98%)
DICE : 16.16 (+4.12%)
IMCR : 37.34 (+0.08%)
Nkarta Announces Closing of Upsized Public Offering of Common Stock and Underwriters’ Full Exercise of Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural...

NKTX : 13.18 (+6.98%)
Up 131% in a Day, Is This Hot Stock a Buy?

Some of its early clinical data look much better than expected.

NKTX : 13.18 (+6.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Nkarta Inc. is a biopharmaceutical company. It develops and commercializes cell therapies for cancer treatment. The company's product candidate includes NKX101 and NKX019, which are in clinical stage. Nkarta Inc. is based in South San Francisco, California.

See More

Key Turning Points

3rd Resistance Point 14.60
2nd Resistance Point 13.92
1st Resistance Point 13.55
Last Price 13.18
1st Support Level 12.50
2nd Support Level 11.82
3rd Support Level 11.45

See More

52-Week High 40.64
Fibonacci 61.8% 28.00
Fibonacci 50% 24.09
Fibonacci 38.2% 20.19
Last Price 13.18
52-Week Low 7.55

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar